Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in diffuse cutaneous systemic sclerosis
NCT05626751Phase 2Terminated
- Sponsor
- Amgen
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of fipaxalparant in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Amgen. Primary endpoints: Forced Vital Capacity Percentage Predicted at 52 weeks, Treatment-Emergent Adverse Events and 2 more. Started Nov 2022; status: terminated.
02
Drugs
fipaxalparant
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT05626751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626751.